Do you want to read an article? Please log in or register.
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Lipids
COMMENTED
Related content
Type 2 Diabetes
Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline
J Clin Endocrinol Metab.
Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Vergès BL
doi: 10.1210/jc.2019-01338.
COMMENTED
Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc20-0941.
COMMENTED
Type 2 Diabetes
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Care.
Caparrotta TM, Blackbourn LAK, McGurnaghan SJ, Chalmers J, Lindsay R, McCrimmon R, McKnight J, Wild S, Petrie JR, Philip S, McKeigue PM, Webb DJ, Sattar N, Colhoun HM, Scottish Diabetes Research Network–Epidemiology Group
doi: 10.2337/dc20-0120.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study
Diabet Med.
Sultan A, Perriard F, Macioce V, Mariano-Goulart D, Boegner C, Daures JP, Avignon A
doi: 10.1111/dme.13364.
COMMENTED
Lipids
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
N Engl J Med.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators
doi: 10.1056/NEJMoa1812792.
COMMENTED
Type 2 Diabetes
Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
Circulation.
Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M, GOULD Investigators.
doi: 10.1161/
Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
Atherosclerosis.
Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez-Tembra M, Civeira F; Dyslipemia Registry of Spanish Arteriosclerosis Society
doi: 10.1016/j.atherosclerosis.
Diabetes - GeneralLipids
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE
Endocr Pract.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M
doi: 10.4158/EP171764.APPGL.
COMMENTED
Diabetes - General
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk
Eur Heart J.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S
doi: 10.1093/eurheartj/ehz149.